Online citations, reference lists, and bibliographies.
← Back to Search

Preparation And Characterization Of Low-molecular-weight Heparin/protamine Nanoparticles (LMW-H/P NPs) As FGF-2 Carrier

Y. Mori, S. Nakamura, S. Kishimoto, M. Kawakami, S. Suzuki, T. Matsui, M. Ishihara
Published 2010 · Materials Science, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
We produced low-molecular-weight heparin/protamine nanoparticles (LMW-H/P NPs) as a carrier for heparin-binding growth factors, such as fibroblast growth factor-2 (FGF-2). A mixture of low-molecular-weight heparin (MW: about 5000 Da, 6.4 mg/mL) and protamine (MW: about 3000 Da, 10 mg/mL) at a ratio of 7:3 (vol:vol) yields a dispersion of microparticles (1–6 μm in diameter). In this study, diluted low-molecular-weight heparin solution in saline (0.32 mg/mL) mixed with diluted protamine (0.5 mg/mL) at a ratio at 7:3 (vol:vol) resulted in soluble nanoparticles (112.5 ± 46.1 nm in diameter). The generated NPs could be then stabilized by adding 2 mg/mL dextran (MW: 178–217 kDa) and remained soluble after lyophilization of dialyzed LMW-H/P NP solution. We then evaluated the capacity of LMW-H/P NPs to protect activity of FGF-2. Interaction between FGF-2 and LMW-H/P NPs substantially prolonged the biological half-life of FGF-2. Furthermore, FGF-2 molecules were protected from inactivation by heat and proteolysis in the presence of LMW-H/P NPs.
This paper references
10.1016/S0002-9149(97)00676-0
In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.
M. Pan (1997)
Complex formation between polyelectrolytes in dilute aqueous solution. Polymer
L Webster (1997)
10.1093/jb/mvn169
Human stem cell factor (SCF) is a heparin-binding cytokine.
S. Kishimoto (2009)
10.1016/J.BIOMATERIALS.2004.07.061
The interaction of chitosan with fibroblast growth factor-2 and its protection from inactivation.
K. Masuoka (2005)
10.1007/978-3-540-46382-5
Polyelectrolytes and Nanoparticles
J. Koetz (2007)
10.1002/(SICI)1099-0488(19990215)37:4<335::AID-POLB7>3.0.CO;2-W
Nonstoichiometric polyelectrolyte complexes: A mathematical model and some experimental results
E. Nordmeier (1999)
10.1002/JBM.A.30688
Controlled release of fibroblast growth factor-2 from an injectable 6-O-desulfated heparin hydrogel and subsequent effect on in vivo vascularization.
S. Nakamura (2006)
10.1021/JP980486U
Complex Formation between Bovine Serum Albumin and Strong Polyelectrolytes: Effect of Polymer Charge Density
K. Mattison (1998)
10.1096/FASEBJ.10.11.8836040
Heparan sulfate: a piece of information.
M. Salmivirta (1996)
10.1016/S0144-8617(96)00035-5
Chitosan-chondroitin sulfate and chitosan-hyaluronate polyelectrolyte complexes. Physico-chemical aspects
A. Denuzière (1996)
10.1055/S-0038-1653794
Studies on the neutralizing effects of protamine on unfractionated and low molecular weight heparin (Fragmin) at the site of activation of the coagulation system in man.
M. Wolzt (1995)
Effect of protein charge heterogeneity in protein-polyelectrolyte complexation. Macromolecules
JM Park (1992)
10.1016/S0378-5173(03)00183-2
Particle size of liposomes influences dermal delivery of substances into skin.
D. Verma (2003)
10.1002/JCP.1041280317
Heparin protects basic and acidic FGF from inactivation
D. Gospodarowicz (1986)
Heparin and lowmolecular heparin, mechanisms of action, phormacokinetics, dosing, monitoring, efficacy, and safety
J Hirsh (2001)
10.1093/GLYCOB/9.7.705
Structural features in heparin that interact with VEGF165 and modulate its biological activity.
K. Ono (1999)
10.4052/TIGG.10.223
Structure and Function of Heparin and Heparan Sulfate; Heparinoid Library and Modification of FGF-Activities
M. Ishihara (1998)
10.1021/MA00027A047
Effects of protein charge heterogeneity in protein-polyelectrolyte complexation
J. Park (1992)
10.1002/MACP.1991.021920308
Characterization and detection of polyanions by direct polyelectrolyte titration
Karl‐Heinz Wassmer (1991)
Heparin and lowmolecular heparin, mechanisms of action, phormacokinetics, dosing, monitoring, efficacy, and safety. Chest
J Hirsh (2001)
10.1246/CL.2008.266
In Vitro Gene Delivery by pDNA/Chitosan Complexes Coated with Anionic PEG Derivatives that Have a Sugar Side Chain
Mayu Hashimoto (2008)
10.1378/CHEST.119.1_SUPPL.64S
Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety.
J. Hirsh (2001)
10.1016/S0142-9612(03)00557-X
Vascularization in vivo caused by the controlled release of fibroblast growth factor-2 from an injectable chitosan/non-anticoagulant heparin hydrogel.
M. Fujita (2004)
10.1016/S0032-3861(96)00650-7
Complex formation between polyelectrolytes in dilute aqueous solution
Lee F. Webster (1997)
10.1002/(SICI)1099-0518(199612)34:17<3485::AID-POLA3>3.0.CO;2-U
Polyelectrolyte complexes. I. Synthesis and characterization of some insoluble polyanion-polycation complexes
S. Dra̧gan (1996)
10.1002/BBPC.19961000654
Stoichiometry and structure of polyelectrolyte complex particles in diluted solutions
H. Dautzenberg (1996)
10.1289/EHP.5999
Skin as a route of exposure and sensitization in chronic beryllium disease.
S. Tinkle (2003)
10.1002/jbm.a.32265
Controlled release of FGF-2 using fragmin/protamine microparticles and effect on neovascularization.
S. Nakamura (2009)
10.1002/JBM.A.31563
Effect of controlled release of fibroblast growth factor-2 from chitosan/fucoidan micro complex-hydrogel on in vitro and in vivo vascularization.
S. Nakamura (2008)
10.1016/0049-3848(94)90136-8
More to "heparin" than anticoagulation.
U. Lindahl (1994)
10.1016/J.POLYMER.2003.10.055
Soluble polyelectrolyte complexes composed of poly(ethylene oxide)-block-poly(sodium methacrylate) and poly(methacryloyloxyethyl trimethylammonium chloride)
Susanna Holappa (2003)



This paper is referenced by
10.26717/BJSTR.2018.12.002265
Low-Molecular Weight Heparin/ProtamineMicro-Nanoparticles Augmented Viability of HumanAdipose-Derived Regenerative Cells
Masashi Sakuma (2018)
10.1016/j.ijbiomac.2015.03.001
Extremophilic polysaccharide nanoparticles for cancer nanotherapy and evaluation of antioxidant properties.
S. Raveendran (2015)
10.1016/j.jss.2014.08.011
Platelet-rich plasma-containing fragmin-protamine micro-nanoparticles promote epithelialization and angiogenesis in split-thickness skin graft donor sites.
Yūki Takabayashi (2015)
10.1016/j.jss.2015.03.022
Improved angiogenesis and healing in crush syndrome by fibroblast growth factor-2-containing low-molecular-weight heparin (Fragmin)/protamine nanoparticles.
Makoto Takikawa (2015)
10.1166/JBN.2014.1878
Self-assembled hyaluronate/protamine polyelectrolyte nanoplexes: synthesis, stability, biocompatibility and potential use as peptide carriers.
A. Umerska (2014)
Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin / Protamine Micro / Nanoparticles
M. Ishihara (2015)
10.3892/ol.2018.8903
FGF2 and FGFR2 in patients with idiopathic pulmonary fibrosis and lung cancer
L. Li (2018)
10.1016/j.jconrel.2014.11.009
Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy.
F. Alam (2015)
Characterization of Highly Heterogeneous Heparin-Protein Complexes Using Novel Mass Spectrometry-Based Approaches
Yunlong Zhao (2017)
10.2217/nnm-2017-0127
Heparin: new life for an old drug.
Carlos Raúl Aláez-Versón (2017)
10.1080/10717544.2017.1333173
Temperature-sensitive heparin-modified poloxamer hydrogel with affinity to KGF facilitate the morphologic and functional recovery of the injured rat uterus
He-Lin Xu (2017)
10.1016/j.reth.2017.11.003
Autologous and heterotopic transplantation of adipose stromal vascular fraction ameliorates stress urinary incontinence in rats with simulated childbirth trauma
K. Inoue (2018)
10.1080/2000656X.2018.1523178
FGF-2-containing dalteparin/protamine nanoparticles (FGF-2&D/P NPs) ameliorate UV-induced skin photoaging in hairless mice
Yūki Takabayashi (2018)
10.3390/polym11040672
Polyelectrolyte Complexes of Natural Polymers and Their Biomedical Applications
M. Ishihara (2019)
HEPARINOID-BASED BIOMATERIALS AND THEIR APPLICATIONS
Masayuki Ishihara (2016)
10.1021/bm501532e
Advanced nanocarriers based on heparin and its derivatives for cancer management.
Xiaoye Yang (2015)
10.2147/CCID.S108187
Enhanced effect of fibroblast growth factor-2-containing dalteparin/protamine nanoparticles on hair growth
Yūki Takabayashi (2016)
10.1016/j.ejpb.2015.04.006
Chondroitin-based nanoplexes as peptide delivery systems--Investigations into the self-assembly process, solid-state and extended release characteristics.
A. Umerska (2015)
10.1155/2013/928790
Improvement of Hydrodynamics-Based Gene Transfer of Nonviral DNA Targeted to Murine Hepatocytes
S. Nakamura (2013)
10.4236/JBNB.2011.225061
Low-Molecular-Weight Heparin and Protamine-Based Polyelectrolyte Nano Complexes for Protein Delivery (A Review Articles)
M. Ishihara (2011)
10.1016/S1773-2247(10)50056-X
Protein-based nanoparticles as a drug delivery system: chances, risks, perspectives
S. Fuchs (2010)
10.1093/jrr/rrx044
Protective effect of FGF-2 and low-molecular-weight heparin/protamine nanoparticles on radiation-induced healing-impaired wound repair in rats
Jun Kinoda (2018)
10.1016/j.nano.2012.12.006
Pharmaceutically versatile sulfated polysaccharide based bionano platforms.
S. Raveendran (2013)
10.1016/B978-0-323-52725-5.00011-3
Platelet-Rich Plasma Incorporated Nanostructures for Tissue Engineering Applications
Mohammad Amin Shamekhi (2017)
10.1002/mabi.201500288
Two-Phase Electrospinning to Incorporate Polyelectrolyte Complexes and Growth Factors into Electrospun Chitosan Nanofibers.
Laura W. Place (2016)
10.1371/journal.pone.0164149
Manufacturing of a Secretoneurin Drug Delivery System with Self-Assembled Protamine Nanoparticles by Titration
B. Scheicher (2016)
10.3390/pharmaceutics4010042
Novel Experimental and Clinical Therapeutic Uses of Low-Molecular-Weight Heparin/Protamine Microparticles
S. Kishimoto (2012)
10.1089/biores.2012.0251
Three-Dimensional Expansion Using Plasma-Medium Gel with Fragmin/Protamine Nanoparticles and FGF-2 to Stimulate Adipose-Derived Stromal Cells and Bone Marrow-Derived Mesenchymal Stem Cells
S. Kishimoto (2012)
A REVIEW ON BIOMEDICAL APPLICATIONS OF CHITOSAN-BASED BIOMATERIALS
M. Ishihara (2015)
Low-Molecular-Weight Heparin and Protamine-Based Polyelectrolyte Nano Complexes for Protein Delivery ( A Review Article )
M. Ishihara (2012)
10.3233/BME-181009
Biomaterials as cell carriers for augmentation of adipose tissue-derived stromal cell transplantation.
M. Ishihara (2018)
10.3390/ma10080929
Smart Carriers and Nanohealers: A Nanomedical Insight on Natural Polymers
S. Raveendran (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar